Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes
- PMID: 27113604
- PMCID: PMC4904718
- DOI: 10.1007/s00415-016-8136-x
Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes
Abstract
Botulinum toxin (BoNT) is highly effective in the treatment of cervical dystonia (CD), yet a significant proportion of patients report low levels of satisfaction following treatment and fail to follow up for repeated treatments. The goal of this study was to determine the reasons that some patients have unsatisfactory responses. A total of 35 subjects who came to our center requesting alternative treatments due to unsatisfactory responses following BoNT treatment for CD were evaluated. Included were 26 women and 9 men with an average age of 57.1 years (range 25-82 years), and an average duration of illness of 12.5 years (range 1-55 years). Details of unsatisfactory BoNT treatments were methodically collected by a movement specialist using a standardized intake form, including provider subspecialty, product used, the number of satisfactory or unsatisfactory trials, doses given, specific muscles treated, the use of electromyographic guidance, side effects, and tests of resistance. The specialist then provided repeat treatments if indicated, and followed each case until the reasons for unsatisfactory outcomes could be determined. Multiple reasons for unsatisfactory outcomes were found. They included suboptimal BoNT doses, suboptimal muscle targeting, intolerable side effects, complex movement patterns, discordant perceptions, and incorrect diagnoses. Only one patient was functionally resistant to BoNT. Of 32 subjects who received repeat BoNT treatments, 25 (78 %) achieved satisfactory responses after revision of the original treatment plan. These results indicate that the majority of unsatisfactory responses to BoNT treatment of CD were caused by correctible factors and imply a need for improved education regarding optimal treatment methods.
Keywords: Botulinum toxin; Treatment failure; Treatment resistance.
Figures

Similar articles
-
Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE).J Neurol Sci. 2015 Feb 15;349(1-2):84-93. doi: 10.1016/j.jns.2014.12.030. Epub 2014 Dec 27. J Neurol Sci. 2015. PMID: 25595221 Clinical Trial.
-
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.Neurology. 1999 Oct 22;53(7):1431-8. doi: 10.1212/wnl.53.7.1431. Neurology. 1999. PMID: 10534247 Clinical Trial.
-
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.Neurology. 1999 Oct 22;53(7):1439-46. doi: 10.1212/wnl.53.7.1439. Neurology. 1999. PMID: 10534248 Clinical Trial.
-
Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal.Expert Opin Drug Saf. 2021 Jun;20(6):695-705. doi: 10.1080/14740338.2021.1915282. Epub 2021 Jun 28. Expert Opin Drug Saf. 2021. PMID: 33831328 Review.
-
Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?Parkinsonism Relat Disord. 2018 Nov;56:16-19. doi: 10.1016/j.parkreldis.2018.06.017. Epub 2018 Jun 15. Parkinsonism Relat Disord. 2018. PMID: 29910156 Review.
Cited by
-
Dynamic muscle paralytic effects of a novel botulinum toxin A free of neurotoxin-associated proteins.Pharmacol Res Perspect. 2022 Jun;10(3):e00955. doi: 10.1002/prp2.955. Pharmacol Res Perspect. 2022. PMID: 35484714 Free PMC article.
-
"Pseudo"-Secondary Treatment Failure Explained via Disease Progression and Effective Botulinum Toxin Therapy: A Pilot Simulation Study.Toxins (Basel). 2023 Oct 18;15(10):618. doi: 10.3390/toxins15100618. Toxins (Basel). 2023. PMID: 37888649 Free PMC article.
-
Medical and Surgical Treatments for Dystonia.Neurol Clin. 2020 May;38(2):325-348. doi: 10.1016/j.ncl.2020.01.003. Epub 2020 Mar 2. Neurol Clin. 2020. PMID: 32279713 Free PMC article. Review.
-
Neutralizing Antibody Formation with OnabotulinumtoxinA (BOTOX®) Treatment from Global Registration Studies across Multiple Indications: A Meta-Analysis.Toxins (Basel). 2023 May 17;15(5):342. doi: 10.3390/toxins15050342. Toxins (Basel). 2023. PMID: 37235376 Free PMC article.
-
Lessons about Botulinum Toxin A Therapy from Cervical Dystonia Patients Drawing the Course of Disease: A Pilot Study.Toxins (Basel). 2023 Jun 30;15(7):431. doi: 10.3390/toxins15070431. Toxins (Basel). 2023. PMID: 37505701 Free PMC article.
References
-
- Evatt ML, Freeman A, Factor S. Adult-onset dystonia. Handb Clin Neurol. 2011;100:481–511. - PubMed
-
- Hallett M, Albanese A, Dressler D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;67:94–114. - PubMed
-
- Sethi KD, Rodriguez R, Olayinka B. Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ. 2012;15:419–23. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical